Healthcare Industry News:  Sanofi-aventis 

Biopharmaceuticals Generics FDA

 News Release - April 12, 2006

Mylan Announces Tentative Approval for Fexofenadine Hydrochloride Tablets

PITTSBURGH, April 12 (HSMN NewsFeed) -- Mylan Laboratories Inc. (NYSE: MYL ) today announced that the U.S. Food and Drug Administration has granted tentative approval for Mylan Pharmaceuticals Inc.'s Abbreviated New Drug Application (ANDA) for Fexofenadine Hydrochloride Tablets, 30mg, 60mg and 180mg. Fexofenadine Hydrochloride Tablets are the AB-rated generic equivalent of Aventis Pharmaceuticals' AllegraŽ Tablets, which had annual U.S. sales of approximately $1.4 billion as of December 31, 2005, according to IMS Health

About Mylan Laboratories

Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories, Inc. that develop, license, manufacture, market and distribute an extensive line of generic and proprietary products.

For more information about Mylan, visit

Source: Mylan Laboratories

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.